What are the survival rates for different stages of ovarian cancer?

Ovarian cancer is a common malignant disease among women. This disease has claimed the lives of many women. For this disease, we hope that women can receive treatment in the early stages of the disease so that their chances of survival are greater. However, many women only discover ovarian cancer in the late stages, so they are very worried about their survival time. In fact, for any cancer, the survival rate is not optimistic when it reaches the late stages. As for the survival time of ovarian cancer in the late stages, I will introduce it to you below.

For doctors, the main function of cancer staging is to monitor the patient's condition and provide a reference for individual prognosis. That is to say, patients with the same stage have similar disease severity, which means it can also be used as a reference for prognosis treatment. It's like patients communicating about their conditions with each other, and doctors from different countries and regions communicating with each other, forming a similar unified standard for reference. In ovarian cancer, the prognosis of patients in different stages varies greatly. According to statistics, the 5-year survival rate of stage I patients is 76%-93%, stage II is 60%-74%, stage IIIA is 41%, stage IIIB is 25%, stage IIIC is 23%, and stage IV is 11%. The later the ovarian cancer stage, the lower the survival rate. Therefore, once ovarian cancer is discovered, patients must be supplemented with selenium as soon as possible. Selenium supplementation can improve immunity, control tumor recurrence, and prolong survival. Staging plays a core role in the diagnosis and treatment of ovarian cancer. Correctly understanding the concept of comprehensive staging and strictly implementing comprehensive staging surgery are not only necessary for accurate assessment of the condition, but also a guarantee for improving treatment effectiveness.

Stage I: The cancer is limited to one or both ovaries or fallopian tubes and has not spread to the abdominal or pelvic organs or lymph nodes.

Stage II: The cancer affects one or both ovaries or fallopian tubes and has spread to pelvic organs such as the uterus, fallopian tubes, bladder, sigmoid colon, or rectum, but has not invaded lymph nodes or distant sites.

Stage IIIA: In addition to cancer in one or both ovaries or fallopian tubes, there are two other conditions: First, the cancer has spread through the pelvic cavity to the abdominal wall. Second, the cancer has spread to the abdominal and dorsal lymph nodes (i.e., retroperitoneal lymph nodes).

Stage IIIB: This is the advanced stage of ovarian cancer, when the cancer has spread to the spleen, liver, lungs, and even other organs outside the abdomen.

The ovaries are two tiny organs, each about the size and shape of an almond, located in the abdomen just below the pelvic bone, just behind a woman. They form part of a woman's reproductive and hormonal system and store a woman's supply of eggs. Every month an egg is released from one of the ovaries and travels through the fallopian tubes to the uterus, ready for fertilization. The ovaries are also responsible for making the female hormones estrogen and progesterone.

Ovarian cancer metastases or secondary cancers are masses that form in other parts of the body due to the spread of ovarian cancer cells. Ovarian cancer cells tend to spread to the surface of the lining of the abdomen (abdomen) called the peritoneum (a large, thin, soft, clear sheet of tissue that covers the organs inside your abdomen) and often form masses in the mesentery, omentum (a layer of fatty tissue that extends down from the stomach), on the surface of the liver, and rarely in the liver, spleen, or lungs. These masses (metastases) often produce excess fluid in the so-called tumor. Ascites can cause noticeable swelling and uncomfortable symptoms.

When you receive an ovarian cancer diagnosis, your medical team's goals are to:

Types and subtypes of ovarian cancer

Ovarian cancer stage (how much cancer there is and how far it has spread)

The grade of ovarian cancer (how quickly it grows and spreads)

We use an international staging system that looks at how far ovarian cancer has spread. This involves scans, examining you during surgery, and taking a number of samples (biopsies). Finding out the stage of the cancer is an important part of the diagnosis because it affects your treatment options. This staging system is called the Figo system, named after its authors - the International Federation of Gynecologic Oncologists (FIGO).

Another staging system is called TNM, which takes into account the size of the tumor (T), whether the tumor has spread to the lymph nodes/lymph nodes (N), and whether the tumor has spread elsewhere in the body (M- for metastasis).

Metastases are masses of cancer cells that grow away from the primary cancer. Cells from the primary cancer can spread to other organs through blood vessels and lymphatic vessels.

How long patients with advanced ovarian cancer survive depends on the patient's own immune tolerance and whether reasonable and standardized treatment methods are chosen during the treatment process.
Generally speaking, according to data from home and abroad, the five-year survival rate of women with advanced ovarian cancer is only 25% to 30%. Therefore, active treatment is very important and can prolong life to a certain extent.
How long is the survival period of patients with advanced ovarian cancer? Generally, in the advanced stage of ovarian cancer, the cancer cells have spread to organs such as the uterus, appendages or pelvic cavity. Therefore, it is a big problem both in diagnosis and treatment. This requires friends to develop a scientific and reasonable treatment plan, which is an important prerequisite for patients to live long-term and improve their quality of life.
Generally, carcinoma in situ can be treated with surgical resection, which is also the most effective method. However, if the ovarian cancer is in the late stage and is invasive, the effect is not ideal because the cancer cells of the late stage ovarian cancer have already spread, so the effect is still relatively poor.